CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition
CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstruc
How this was made
The 30-second read
Why it matters
Traders can update valuation drivers across three buckets: (1) MYQORZO commercialization traction and international market access, (2) clinical de-risking from ACACIA-HCM topline results and upcoming ESC presentation, and (3) balance-sheet risk reduction from a large equity raise.
Market read
The filing combines commercial KPIs, Phase 3 de-risking, and a major capital raise, creating multiple near-term catalysts for CYTK positioning.
What to watch
Key near-term swing factors are the supplemental NDA timing for nHCM (Q4 2026) and how LVEF-related safety patterns translate into prescribing behavior and payer acceptance.
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
MYQORZO generated $25.3 million of net product revenue and the company reported expanding prescribing and patient access, but total revenue declined to $28.6 million from $66.8 million and net loss widened to $198.8 million from $134.4 million as commercial-launch spending increased.
Actuals vs. the company’s prior outlook
from its previous release| Metric | Guided | Reported | Verdict |
|---|---|---|---|
| GAAP combined R&D and SG&A Expense | $830 million to $870 million | Not reported for full year 2026 | n/a |
| Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expense | $130 million to $120 million | Not reported for full year 2026 | n/a |
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $28.6 million | – | – |
| MYQORZO net product revenueGAAP | $25.3 million | – | – |
| MYQORZO net product revenue from the U.S.GAAP | $23.0 million | – | – |
| MYQORZO net product revenue from EuropeGAAP | $2.3 million | – | – |
| Collaboration revenueGAAP | $3.3 million | – | – |
| License and milestone revenuesGAAP | did not have any license and milestone revenues | – | – |
| Research and development expensesGAAP | $97.8 million | – | – |
| Non-cash stock-based compensation expense included in R&D expensesGAAP | $15.9 million | – | – |
| Selling, general and administrative expensesGAAP | $104.4 million | – | – |
| Non-cash stock-based compensation expense included in SG&A expensesGAAP | $19.8 million | – | – |
| Cost of goods sold related to MYQORZOGAAP | $2.7 million | – | – |
| Collaboration cost of revenuesGAAP | $2.9 million | – | – |
| Net lossGAAP | $198.8 million | – | – |
| Net loss per share, basic and dilutedGAAP | $(1.50) per share, basic and diluted | – | – |
| Cash, cash equivalents and investmentsother | approximately $1.7 billion | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| MYQORZO net product revenueInclusive of $23.0 million from the U.S. and $2.3 million from Europe reflecting initial inventory purchased by distributors in Germany. | $25.3 million | – | – |
| MYQORZO net product revenue from the U.S.Continued U.S. commercial launch, with increasing physician and patient awareness driven by strong engagement and successful marketing campaigns. | $23.0 million | – | – |
| MYQORZO net product revenue from EuropeReflecting initial inventory purchased by distributors in Germany. | $2.3 million | – | – |
| Collaboration revenueCollaboration revenue compared to $2.4 million for the same period in 2025. | $3.3 million | – | – |
full year 2026 outlook
- Operating expensesGAAP combined R&D and SG&A Expense $860 million to $890 million
- NoteNon-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expense $140 million to $130 million
What drove it
- Over 700 unique healthcare providers prescribed MYQORZO as of June 30, 2026.
- Approximately 1,500 patients were dispensed MYQORZO as of June 30, 2026.
- Over 80% of patients on therapy were on paid prescription as of June 30, 2026.
- MYQORZO launched in Germany in June.
- ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 in KCCQ Clinical Summary Score and maximal exercise performance.
- The company expects to file a Supplemental NDA for nHCM in Q4 2026.
Concerns
- Total revenues were $28.6 million compared to $66.8 million for the same period in 2025, when the company recorded $64.4 million of license and milestone revenues.
- Net loss was $198.8 million, compared to a net loss of $134.4 million for the same period in 2025.
- SG&A expenses were $104.4 million compared to $65.7 million, primarily due to costs associated with the commercial launch of MYQORZO and higher personnel-related costs, including stock-based compensation.
- Current GAAP combined R&D and SG&A expense guidance is $860 million to $890 million, compared with prior guidance of $830 million to $870 million.
- LVEF <50% occurred in 10% of participants taking aficamten and in 1% of participants taking placebo in ACACIA-HCM. Two participants on aficamten experienced a serious adverse event of heart failure associated with LVEF <50%.
- The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities.
What to watch
- Primary results from ACACIA-HCM are scheduled for presentation in a Hot Line Session at the European Society of Cardiology Congress in August 2026.
- The company expects to submit a Supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.
- The company expects to complete trial conduct for the Japan cohort of ACACIA-HCM in Q3 2026.
- The company expects to complete trial conduct for CAMELLIA-HCM in Q3 2026.
- The company expects to continue patient enrollment in COMET-HF through 2026.
- The company expects to complete patient enrollment in Cohort 1 of AMBER-HFpEF in the second half of 2026.
- The company expects to launch in more than five additional markets by the first half of 2027.
Balance sheet and cash flow
- As of June 30, 2026, the company had approximately $1.7 billion in cash, cash equivalents and investments compared to $1.1 billion at March 31, 2026.
- In the second quarter, the company completed a public offering of 11,338,028 shares of its common stock, including the underwriters’ exercise in full of their option to purchase additional shares, at a price of $71.00 per share.
- Net proceeds to the Company from the offering were approximately $760.1 million, after deducting underwriting discounts and commissions and offering expenses payable to the Company.
Analysis
The second quarter marked the initial commercial revenue contribution from MYQORZO, which generated $25.3 million of net product revenue. The U.S. contributed $23.0 million and Europe contributed $2.3 million, reflecting initial inventory purchased by distributors in Germany. Commercial indicators showed expanding access, with over 700 unique healthcare providers prescribing MYQORZO, approximately 1,500 patients dispensed the drug, and over 80% of patients on therapy on paid prescription as of June 30, 2026.
Total revenue was $28.6 million compared to $66.8 million in the same period in 2025. The comparison reflects the absence of license and milestone revenue in the current quarter, versus $64.4 million in the prior-year quarter. Collaboration revenue was $3.3 million compared with $2.4 million. The revenue mix has shifted to product revenue, although the filing does not provide prior-year or prior-quarter MYQORZO product-revenue comparisons.
Operating spending remained elevated around commercialization and pipeline development. R&D expense was $97.8 million compared to $110.1 million, with the decrease primarily attributed to higher clinical trial activity, supply chain costs, and medical affairs activities in 2025, partly offset by higher personnel-related costs in 2026. SG&A expense increased to $104.4 million from $65.7 million, primarily due to MYQORZO launch costs and higher personnel-related costs. Net loss widened to $198.8 million, or $(1.50) per share, basic and diluted, from $134.4 million, or $(1.12) per share, basic and diluted.
The company strengthened its funding position through a public offering of 11,338,028 shares at $71.00 per share, generating approximately $760.1 million in net proceeds. Cash, cash equivalents and investments were approximately $1.7 billion at June 30, 2026, compared to $1.1 billion at March 31, 2026. No operating cash flow, free cash flow, or debt figure was reported in the provided filing text.
For full year 2026, Cytokinetics increased GAAP combined R&D and SG&A expense guidance to $860 million to $890 million from $830 million to $870 million. The company said the increase is primarily driven by commercial-readiness investments prompted by positive ACACIA-HCM results to support a potential 2027 MYQORZO launch in nHCM. The central upcoming catalysts identified in the filing are the August 2026 ACACIA-HCM presentation and the expected Q4 2026 supplemental NDA submission.
Management, verbatim
Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline, both hallmarks of continued strong execution for our maturing business. In the U.S., we continued to build launch velocity evidenced by expanding physician adoption and increasing patient access. Internationally, we launched MYQORZO in Germany and laid the foundation for broadening access to aficamten by submitting reimbursement dossiers alongside regulatory filings advancing in multiple countries in Europe.
Robert I. Blum, President and Chief Executive Officer
We look forward to sharing results from ACACIA-HCM later this month and submitting a supplemental NDA to the U.S. Food and Drug Administration in the fourth quarter. Having also secured additional capital during the recent quarter, we have the financial resources to invest in both the global commercialization of MYQORZO and the continued progression of our pipeline, positioning us well to maximize the potential of our specialty cardiology franchise.
Robert I. Blum, President and Chief Executive Officer
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss
- Tax expense, tax rate, and effective tax rate
- Non-GAAP revenue, earnings, EPS, or operating-expense measures
- Operating cash flow
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Full-year 2026 revenue guidance
- Full-year 2026 gross-margin guidance
- Full-year 2026 tax-rate guidance
- Actual full-year 2026 GAAP combined R&D and SG&A expense for comparison with prior guidance
- Actual full-year 2026 non-cash stock-based compensation expense included in GAAP combined R&D and SG&A expense for comparison with prior guidance
- Prior-quarter total revenue, R&D expense, SG&A expense, net loss, and EPS
- Year-over-year and quarter-over-quarter percentage changes for reported financial metrics
- Prior-year MYQORZO product revenue by total, U.S., and Europe
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and a business update for Cytokinetics’ aficamten (MYQORZO) and other cardiac muscle programs.
Ticker impact
Cytokinetics reported Q2 2026 results, MYQORZO launch metrics, and positive ACACIA-HCM topline data, plus a $760.1M equity offering.
Bullish bias with potential volatility around ACACIA-HCM presentation timing and supplemental NDA expectations.
The filing discloses multiple fresh catalysts: MYQORZO prescribing/dispensing and international approvals, ACACIA-HCM meeting both primary endpoints with no new safety signals, and a sizable capital raise that reduces funding risk.
Market effects
Reinforces investor appetite for cardiology specialty pharma with myosin-modulator franchises and can lift sentiment for adjacent HCM/HF development programs.
European reimbursement and regulatory progress (UK, Netherlands, Germany; filings in Canada/Switzerland) supports broader EU commercialization expectations.
International regulatory and collaboration-driven filings (Sanofi in HK/Taiwan; Bayer in Japan) highlight global execution, which can influence cross-region biotech risk appetite.
Counterpoint
The equity offering and revenue decline versus prior year can temper enthusiasm, and topline Phase 3 results still require full data, regulatory review, and commercial uptake durability.
Key entities
- issuerCytokinetics, Incorporated
Nasdaq-listed company reporting Q2 2026 results, MYQORZO launch metrics, and ACACIA-HCM topline data.
- productMYQORZO (aficamten)
Cardiac myosin inhibitor with ongoing U.S. launch and international regulatory/reimbursement progress.
- clinical_trialACACIA-HCM
Phase 3 trial in symptomatic non-obstructive hypertrophic cardiomyopathy; topline results reported as meeting both dual primary endpoints.
- regulatory_milestoneFDA supplemental NDA
Company expects to submit a supplemental NDA for nHCM in Q4 2026.
